SEC Form 4 · accession 0001193125-26-386431
Artiva Biotherapeutics, Inc. · ARTV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred Aslan
Officer — Chief Executive Officer · Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 9, 2026 · 4:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001817241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 8, 2026 | S | 23,429 | $10.9158 | D | 1,449,765 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026.
- F2The weighted average sale price for the transaction reported was $10.9158, and the range of prices were between $10.72 and $11.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.